Why buy this course?

The course you are looking at is not like any other e-Learning course you have ever taken.
Watch this short video to learn why!

Benchmark: FDA Proposed Rule: Nonclinical Testing Terminology Updates for Drug and Biologic Regulation

Take this benchmark to assess how much you would benefit from taking the course on the FDA Proposed Rule on Nonclinical Testing Terminology.

This quick check helps you gauge your grasp of why the FDA is modernizing language (from “animal” to “nonclinical”), what that signals for new approach methodologies (NAMs), and how it could affect planning, submissions, and stakeholder input.

  • Clarify the rule’s intent: why terminology matters and what flexibility it enables.
  • See who is impacted most (sponsors, reviewers, collaborators) and where workflows may shift.
  • Weigh practical trade‑offs: innovation vs. evidentiary rigor; flexibility vs. consistency.
  • Spot immediate readiness steps (templates, SOPs, engagement with FDA).
  • Decide whether a deeper dive will save you rework, risk, or time.

Outcome: You’ll know whether this course can sharpen your strategy for using NAMs, preparing IND/NDA content, and making effective public comments—before you invest more time.

NOTE: Unless otherwise indicated, all course purchases are for access to the course for a period of 1-year. At the end of the one year term, the course will be set to “inactive”.

Federal Register Title
This benchmark will help determine your readiness for: Federal Register Document titled Nonclinical Testing Terminology. Document Number: 2026-19349

Buy this Course
FR-26-2221-1

About Benchmarks:

Are you ready for this regulation? Use this benchmark to find out.

Each benchmark is build directly for the federal regulation.  They reflect the learning objectives of the related course.

The benchmark is not a “trivia test” – they help you evaluate your readiness to apply the new regulation.

Contact us for more information and/or personalized benchmarks for your specific organization/industry.

Benchmark: FDA Proposed Rule: Nonclinical Testing Terminology Updates for Drug and Biologic Regulation

Take this benchmark to assess how much you would benefit from taking the course on the FDA Proposed Rule on Nonclinical Testing Terminology.

This quick check helps you gauge your grasp of why the FDA is modernizing language (from “animal” to “nonclinical”), what that signals for new approach methodologies (NAMs), and how it could affect planning, submissions, and stakeholder input.

  • Clarify the rule’s intent: why terminology matters and what flexibility it enables.
  • See who is impacted most (sponsors, reviewers, collaborators) and where workflows may shift.
  • Weigh practical trade‑offs: innovation vs. evidentiary rigor; flexibility vs. consistency.
  • Spot immediate readiness steps (templates, SOPs, engagement with FDA).
  • Decide whether a deeper dive will save you rework, risk, or time.

Outcome: You’ll know whether this course can sharpen your strategy for using NAMs, preparing IND/NDA content, and making effective public comments—before you invest more time.

NOTE: Unless otherwise indicated, all Benchmarks are free of charge!

Federal Register Title
This benchmark will help determine your readiness for: Federal Register Document titled Nonclinical Testing Terminology. Document Number: 2026-19349

Buy this Course
FR-26-2221-1

Replenish your Studio Course Advisor Unit balance here . Please contact frsales@courseavenue.com if you need to purchase more. Talk to use about an Enterprise License to see if that is right for you!

Benchmark: FDA Proposed Rule: Nonclinical Testing Terminology Updates for Drug and Biologic Regulation

Federal Register Title
This benchmark will help determine your readiness for: Federal Register Document titled Nonclinical Testing Terminology. Document Number: 2026-19349

Buy this Course
FR-26-2221-1

Take this benchmark to assess how much you would benefit from taking the course on the FDA Proposed Rule on Nonclinical Testing Terminology.

This quick check helps you gauge your grasp of why the FDA is modernizing language (from “animal” to “nonclinical”), what that signals for new approach methodologies (NAMs), and how it could affect planning, submissions, and stakeholder input.

  • Clarify the rule’s intent: why terminology matters and what flexibility it enables.
  • See who is impacted most (sponsors, reviewers, collaborators) and where workflows may shift.
  • Weigh practical trade‑offs: innovation vs. evidentiary rigor; flexibility vs. consistency.
  • Spot immediate readiness steps (templates, SOPs, engagement with FDA).
  • Decide whether a deeper dive will save you rework, risk, or time.

Outcome: You’ll know whether this course can sharpen your strategy for using NAMs, preparing IND/NDA content, and making effective public comments—before you invest more time.

Related products